GoAI
Get started
Veracyte, Inc. logo

Veracyte, Inc.

VCYT

NASDAQHealthcareMedical - Diagnostics & Research

Open in GoAI

Previous close

$42.31

+$0.52 · +1.24%

Aug 21, 4:00 PM ET

VCYT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

37

Expensive

Momentum

69

Gaining

Sentiment

60

Mixed

Risk resilience

53

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
Marc Stapley
Listed since
Oct 29, 2013
Employees
755

Market position

Day range

Current $42.31

52-week range

Current $42.31

Open
$42.18
Previous close
$41.79
Volume
1.01M
0.81× average
Average volume
1.23M
Average daily volume
Market cap
3.38B USD
Beta
1.94
Market reference 1
50-day average
$52.4055
-19.26% below average
200-day average
$42.5202
-0.49% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.99B USD
EV / EBITDA
33.31×
Earnings yield
2.01%
Free cash flow yield
3.83%

Profitability & efficiency

Return on equity
5.07%
Return on assets
4.72%
Return on invested capital
5.34%

Financial health

Current ratio
8.15×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends80%38%-5%-48%Gross margin, FY2021: 66.11%Gross margin, FY2022: 65.74%Gross margin, FY2023: 68.73%Gross margin, FY2024: 66.88%Gross margin, FY2025: 69.62%Operating margin, FY2021: -37.31%Operating margin, FY2022: -13.85%Operating margin, FY2023: -23.76%Operating margin, FY2024: 3.62%Operating margin, FY2025: 14.34%Net margin, FY2021: -34.42%Net margin, FY2022: -12.33%Net margin, FY2023: -20.61%Net margin, FY2024: 5.41%Net margin, FY2025: 12.83%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 66.11%. Gross margin FY2022 65.74%. Gross margin FY2023 68.73%. Gross margin FY2024 66.88%. Gross margin FY2025 69.62%. Operating margin FY2021 -37.31%. Operating margin FY2022 -13.85%. Operating margin FY2023 -23.76%. Operating margin FY2024 3.62%. Operating margin FY2025 14.34%. Net margin FY2021 -34.42%. Net margin FY2022 -12.33%. Net margin FY2023 -20.61%. Net margin FY2024 5.41%. Net margin FY2025 12.83%.

Income trends

Revenue

517.15M USD+16.01%

Operating income

74.15M USD+359.36%

Net income

66.35M USD+174.89%
Income trends across reported periods577.44M USD336.26M USD95.09M USD−146.09M USDRevenue, FY2021: 219.51M USDRevenue, FY2022: 296.54M USDRevenue, FY2023: 361.05M USDRevenue, FY2024: 445.76M USDRevenue, FY2025: 517.15M USDOperating income, FY2021: −81.9M USDOperating income, FY2022: −41.08M USDOperating income, FY2023: −85.8M USDOperating income, FY2024: 16.14M USDOperating income, FY2025: 74.15M USDNet income, FY2021: −75.56M USDNet income, FY2022: −36.56M USDNet income, FY2023: −74.4M USDNet income, FY2024: 24.14M USDNet income, FY2025: 66.35M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 219.51M USD. Revenue FY2022 296.54M USD. Revenue FY2023 361.05M USD. Revenue FY2024 445.76M USD. Revenue FY2025 517.15M USD. Operating income FY2021 −81.9M USD. Operating income FY2022 −41.08M USD. Operating income FY2023 −85.8M USD. Operating income FY2024 16.14M USD. Operating income FY2025 74.15M USD. Net income FY2021 −75.56M USD. Net income FY2022 −36.56M USD. Net income FY2023 −74.4M USD. Net income FY2024 24.14M USD. Net income FY2025 66.35M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue517.15M USD445.76M USD361.05M USD296.54M USD219.51M USD
Cost of goods sold157.1M USD147.62M USD112.9M USD101.58M USD74.4M USD
Gross profit360.05M USD298.15M USD248.15M USD194.95M USD145.11M USD
Research and development70.81M USD69.29M USD57.31M USD40.6M USD29.84M USD
Selling, general, and administrative210.95M USD206.04M USD184.23M USD174.08M USD181.19M USD
Operating expenses285.9M USD282M USD333.94M USD236.04M USD227.02M USD
Interest income—11.15M USD7.34M USD1.97M USD135K USD
Interest expense—2K USD15K USD198K USD241K USD
Depreciation and amortization21.42M USD23.46M USD27.19M USD29.25M USD21.23M USD
Operating income74.15M USD16.14M USD−85.8M USD−41.08M USD−81.9M USD
Net income66.35M USD24.14M USD−74.4M USD−36.56M USD−75.56M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
0.82
FY2025 · +164.52% year over year
Latest fiscal-year revenue
517.15M USD
FY2025 · +16.01% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend1.010.24-0.53-1.3FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend546.91M427.86M308.8M189.75MFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$55.57

31.34% upside
Past 12 months12-month forecastHigh $69.00Average $55.57Low $44.00

VCYT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding VCYT

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
204.15M
Weight
0.18%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
117.72M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
86.11M
Weight
0.11%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
84.99M
Weight
0.05%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
First Trust NYSE Arca Biotechnology Index Fund logoFirst Trust NYSE Arca Biotechnology Index FundFBT
Market value
66.11M
Weight
2.27%
AUM
2.94B USD
Expense ratio
0.55%
Price / 1D
$271.07+1.10%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
65.46M
Weight
0.57%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
49.24M
Weight
0.11%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
ARK Innovation ETF logoARK Innovation ETFARKK
Market value
42.72M
Weight
0.64%
AUM
5.56B USD
Expense ratio
0.75%
Price / 1D
$86.21+3.53%

Continue in GoAI

Research VCYT

research.disclaimer